Glibornuride

CAS: 26944-48-9

Ref. 3D-FG43275

Informação sobre produto

• Nome: Glibornuride
• Sinónimos: Benzenesulfonamide, N-[[(3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]hept-2-yl)amino]carbonyl]-4-methyl-, [1S-(endo,endo)]-, Benzenesulfonamide, N-[[[(1S,2S,3R,4R)-3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]hept-2-yl]amino]carbonyl]-4-methyl-, Gluboride, Glutril, N-[(3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]hept-2-yl)carbamoyl]-4-methylbenzenesulfonamide, N-[[[(1S,2S,3R,4R)-3-Hydroxy-4,7,7-trimethylbicyclo[2.2.1]hept-2-yl]amino]carbonyl]-4-methylbenzenesulfonamide, Ro 6-4563, Ro 6-4563/8, Urea, 1-(2-hydroxy-3-bornyl)-3-(p-tolylsulfonyl)-, (1R,2R,3S,4S)-, endo, endo-1-[(1R)-(2-Hydroxy-3-bornyl)]-3-(p-tolylsulfonyl)urea, endo,endo-1-(2-Hydroxy-3-bornyl)-3-(p-tolylsulfonyl)urea

Descrição

Glibornuride is a drug that inhibits dipeptidyl peptidase-IV (DDP-IV), which is an enzyme that degrades GLP-1, a hormone that stimulates insulin secretion from the pancreas. It has been shown to have significant hypoglycemic effect in patients with type 2 diabetes mellitus and it can be used as an antidiabetic agent. Glibornuride also inhibits sodium-dependent glucose co-transporters and fat synthesis. The drug has been found to have potential for use in the treatment of liver diseases such as nonalcoholic fatty liver disease by inhibiting the activity of lipogenic enzymes and reducing levels of fatty acid. Glibornuride is metabolized by cytochrome P450 enzymes in the liver cells to form its active form, glibenclamide, which then binds to ATP-sensitive potassium channels on hepatocytes, thereby reducing the release of glucose into blood.
Glibornuride

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 366.48 g/mol
• Fórmula: C₁₈H₂₆N₂O₄S
• Pureza: Min. 95%